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Introduction 
Ever since the beginnings of experimental immunology at the end of the nineteenth 
century, scientists have exploited the specificity of antibodies to detect, isolate and 
analyze biological material. The power of antibodies as probes for biological structure 
underwent a quantum increase in 1975, when Kohler and Milstein developed the 
technique for production of Hybridomas. Hybridomas are immortal somatic cell hybrids 
that secrete Monoclonal antibodies (MAbs) of predefined specificity. These antibody-
secreting cell lines can be established routinely and maintained in vitro. By combining the 
nudei of normal antibody-forming cells with those of their malignant counterparts, Kohler 
and Milstein developed a powerful way of analyzing and purifying individual molecules , 
within the enormously complex mixtures in biological material. 
In order to understand the revolutionary impact of monoclonal antibodies, 
it is necessary to understand the problems and limitations of conventional serology. While 
the specificity of antibodies proVided a way of overcoming the enormous complexity of 
biological material, the production of highly specific antisera was diffiqJlt and unreliable. It 
required highly purified antigen. However, using hybridoma technology it is now possible 
to produce unlimited quantities of exquisitely specific antibodies against virtually any 
molecule, regardless of the purity of the immunizing antigen. The fine specificity, degree 
of cross-reaction, affinity and physical properties of antibodies may be selected to suit 
individual needs. 
Conventionally, polyclonal antibodies are prepared in rabbits for use in 
diagnostiCS, serotyping and vaccine development. Rabbit antiserum contains many 
different types of antibodies derived from several plasma cell clones that are specific to 
dlffere'lt epilopes. The u~" of these t ixed populations of antibodies creates a variety of 
dlfierent problems in Immunochemical techniques such as bael,ground rea 'on and false 
positives. The availability of antiserum in limited quantities is also a serious drawback. 
Therefore the preparation of large quantity of homogenous antibodies with a defined 
specificity was a long-standing goal of immunochemical research. This was achieved with 
the development of hybridoma technology for production of MAbs. 
Production of Hybridoma 
In animals, antibodies are synthesized primarily by plasma cells, which are 
terminally differentiated B Lymphocytes. Because plasma cells cannot be grown in tissue 
culture, they cannot be used as an in vitro source of antibodies. For decades, 
immunologists have sought ways of produdng homogenous antibodies of defined 
specificity. Hybridoma technology allows the growth of clonal populations of cells secreting 
antibodies with a defined specificity. Here, antibody-secreting cells isolated from an 
immunized animal is fused with myeloma cell, a type of B cell tumor from BALB/c mice. 
These hybrid cells or hybridoma can be cloned and maintained in vitro to secrete 
antibodies with a defined specificity, which are known as monoclonal antibodies. 
The usefulness of monoclonal antibodies stems from three characteristics -
specificity of binding, homogeneity and ability to be produced in unlimited quantities. 
Another unique advantage of hybridoma production is that impure antigens can be used 
to produce specific antibodies. Because hybridomas are single cell cloned prior to use, 
monospecific antibodies can be produced after immunizations with complex mixtures of 
antigens. However, it would be wrong to think that monoclonal antibodies will completely 
replace conventional serology. The production of monoclonal antibodies involves a great 
deal of work, and a high level of commitment. There will often be occasions when the 
effort required may not be justified. They are not the best choice for certain 
immunochemical techniques. In theory, either as Single antibody preparations or as pools, 
monoclonal antibodies can be used for all of the tasks that require or benefit from the use 
of polyclonal antibodies. In practice, however, producing exactly the right set of 
monoclonal antibodies is often a difficult and laborious job. 
In a hybridoma, the myeloma cells provide the correct genes for continued cell 
division in tissue culture, and the antibody secreting cells provide the functional 
immunoglobulin genes. Hybridomas can be prepared by fusing myelomas and antibody 
secreting cells isolated from different species, but the number of viable hybridomas 
increases dramatically when closely related species are used. Therefore fusions are 
~:Jrmally done ,\ ith crl' foom the same spp.cic~. N c ·mr. ,only used r~<Juse strains can 
serve as succe.sful fus,c. partrlers with 5ALB/c myelomas, however Imrnunizations are 
normally done in BALB/c rnice. 
Polyethylene gly~ol (PEG) is the most commonly used agent to fuse cells in 
hybridoma production. PEG fuses the plasma membranes of adjacent myeloma and/or 
antibody-secreting cells, forming a single cell with two or more nuclei. This heterokaryon 
retains these nuclei until the nuclear membranes dissolve prior to mitosis. During mitosis 
and further rounds of division, the individual chromosomes are segregated into daughter 
cells. Because of the abnormal number of chromosomes, segregation does not always 
deliver identical sets or chromosomes to daughter cells, and chromosomes rnay be lost. If 
one of the chromosomes that carries a functional, rearranged irnmunoglobulin heavy or 
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light chain gene is lost, productIOn of antibody will stop. In a culture of hybridoma cells, 
this will be seen phenotypically as a decrease in antibody titer and will result in unstable 
lines. If the chromosome that is lost contains a gene used in drug selection, then the 
growth of the hybridoma will be unstable, and cells will continue to die during selection. 
Drug selection for elimination of unfused myeloma cells 
Even in the most efficient hybridoma fusions, only about 1% of the starting cells 
are fused, and only about 1 in 105 form viable hybrids. This leaves a large number of 
unfused cells still in culture. The cells from the immunized animal (antibody secreting cell ) 
do not continue to grow in tissue culture and so do not confuse further work. However, 
the myeloma cells are well adapted to tissue culture and must be killed, which can be 
achieved by drug selection. Commonly, the myeloma partner has a mutation in one of the 
enzymes of the salvage pathway of purine nudeotide biosynthesis. For ego Selection with 
8- azaguanine otten yields a cell line harbouring a mutated hypoxanthine-guanine 
phosphoribosyl transferase gene (HPRT). The addition of any compound that blocks the 
de novo nucleotide synthesis pathway will force cells to use the salvage pathway. Cells 
containing a non-functional HPRT protein will die in these conditions. Hybrids between 
myelomas with a nonfunctional HPRT and cells with a functional HPRT will be able to 
grow. Selections are commonly done with aminopterin, methotrexate or azaserine. 
Stages of Hybridoma Production 
It is convenient to divide the production of monoclonal antibodies into three 
stages: (1) immunizing mice, (2) developing the screening procedure, and (3) producing 
hybridomas. 
Animals are injected with an antigen preparation, and once a good humoral 
response has appeared in the immunized animal, an appropriate screening procedure is 
developed. The sera from test bleeds are used to develop and validate the screening 
procedure. After an appropriate screen has been established, the actual production of the 
hyt>nO"fr-as C? 1l beglfl. So>veral C • ,s r'l' ·r to th. f 80n, animals are boosted with a sample 
c • '1. F· r r < '0' ,I, ,>C' - • ct' lis afe prepared from tIe imml'nized 
" t' \'" r ,e" ,~ct:. .. ~ alia iu5ed. i ... T Ul fusion, cells ,iff, a"ut"Q If sei~ive 
medIum and plated in multiwell tissue culture dishes. Hybridomas are ready to test 
beginning about 1 week atter the fusion. Cells from positive well are grown and then 
single-cell cloned. Single-cell cloning ensures that cells that produce the antibody of 
interest are truly monodonal and that the secretion of this antibody can be stably 
maintained. 
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Characterization of Clones 
The total characterization of a MAb is a long and complex procedure, which varies 
widely with the intended use of the antibody. If a single hybridoma has been produced 
and is intended for a specific function it is unlikely that the antibody produced will have all 
the required characteristics. To produce MAb superior to conventional sera for most highly 
specialized functions it is better to make a large panel of cloned hybridomas and further 
select from these by characterization of the antibodies they produce. 
Antibody produced by a clone belongs to one single class, and hence antibody 
class indicates number of clones in a population. Antibody class is most readily determined 
by the use of class specific antibodies in an EUSA or by Ouchtherlony assay. 
Determination of antibody class does not constitute final proof that an antibody is 
monoclonal. For some of the more sophisticated uses of MAbs this is essential. While it is 
likely that there is only one cell type if the antibody produced can be shown to be only of 
the IgM class, it remains possible that there are two or more IgM-secreting hybridomas in 
the culture. An isoelectric focusing gel is the only final method of proof. 
Storage of Hybridoma 
Hybridoma and myeloma cell lines can be stored at -BODC or liquid nitrogen by 
slowly freezing cells in an appropriate solution of nutrients and a cryoprotectant such as 
d imethyls~lphoxide (DMSO). Freezing of cells, which have not been cloned after the 
primary fusion is not always successful, presumably because of overgrowth by non-
producing cells. However, the parent myeloma and established hybridomas can be stored 
with little difficulty. The cells are centrifuged and resuspended at 5-10 X 106 cells/ml in 
medium containing FCS and DMSO. Aliquots of this suspension are then pipetted into 
plastic storage ampoules and frozen slowly at -70DC for at least 12 h and then stored at-
BODe or transferred to liquid nitrogen 
Production of MAbs 
MAb production ' Vitro 
Mabs car ' producf'~ in vitro and in vivo. For production in vitro, hybridomas are 
best expanded slowly by transfer to 24 well tissue culture plates followed by 25 cm2 flask 
and a 75 cm2 flask containing suitable medium such as Dulbecco's Modification of Eagles 
Medium, DMEM or Rosewell Park Memorial InstiMe (RPMI) medium, containing sera (fetal 
calf serum, FCS), antibiotics and other required chemicals. The cell density is maintained 
between lOS and 106 cells/ml. Typical culture supernatants yield up to l00~gjml of 
antibody, the exact amount depending upon the cell density and rate of growth. Culture in 
vitro provides a more pure preparation of antibody. The only contaminants are from the 
FCS. Contamination may be further reduced by the use of serum-free medium. 
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MAb production in vivo 
For producing MAbs in vivo, mice are primed by intraperitoneal injection of 0.5 ml 
pristine (tetra methyl pentadecane) 5 - 10 days before intraperetoneal inoculation with lOs 
- 107 hybridoma cells. It is important to use mice, which are histocompatable with the 
parent cells. The rate of growth of the resulting ascites tumour is in general very variable 
and can be from less than two or more than five weeks. The ascites fluid can be collected 
from an anaesthetized mouse. It is possible to obtain 10 ml of ascites fluid or more from a 
mouse by regular tapping. Ascites cells recover from freezing exceptionally well and can 
be frozen down in the same way as tissue culture cells and reintroduced into animals 
without difficulty. Ascites fluid will be contaminated with mouse imunoglobulins to a small 
extent and if a very pure antibody is required this may prove inconvenient. 
Purification and storage of MAbs 
In many cases, purification of antibody is not necessary since all that is required is 
specificity and each batch of antibody can be tested for titre and used directly. However, if 
a MAb is required as a standard reagent or for therapeutic purposes it must obviously be 
purified. In addition, many of the methods used to characterize a MAb involve labelling it 
with either enzymes or isotopes and a pure antibody is obviously more suitable for this 
purpose. Before purification it is important to determine the class of antibody. As with all 
protein-purification techniques, antibodies may be separated according to charge or size. 
In addition, they may be purified by affinity chromatography utilizing protein A for certain 
types and species, by anti-immunoglobulin columns, or by antigen affinity columns if large 
amounts of antigen are available. 
Most MAbs are stable and can be frozen and thawed readily. It is, however, 
advisable to check the titre after freezing and thawing at an early stage. Many IgM 
antibodies do not retain full antigen-binding capacity after freezing and thawing but many 
do. In general, an antibody, which does not freeze well, is better discarded unless it is of 
considerable importance in which case it should be stored in 0.1 % sodium azide at 4°C. 
MAbs like serum should not be repeatedly frozen and thawed and it is best to freeze 4 or 
5 small aliquots from each tissue culture flask or ascites fluid, from the bulk for general 
use or for testing before purification on large scale. 
Applications of Monoclonal Antibodies In Mariculture 
Hybridoma technology for production of monoclonal antibodies has contributed 
Significantly to aquaculture. Monoclonal antibodies are being employed in disease 
diagnosis, pathogen classification, epidemiological analysis and development of vaccines. 
Outbreak of disease problems of the cultured fish/shellfish is a major bottleneck 
faced by aquaculturists. Generally we go for routine diagnostic procedures like 
microbiological examination and histopathology, which are time consuming. Development 
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of rapid immunodiagnostic techniques based on polyclonal antisera is faced by problems 
of cross-reactions and inconsistency in results. If MAb based diagnostic kits (which are 
more specific) are available for important microbial pathogens, it will help us in adopting 
more scientific health management measures. MAbs can be used to confirm the presence 
of pathogens fixed in tissue sections or tissue imprints by immunohistochemistry, 
particularly useful for detecting low-level infections, which would be overlooked by 
traditional methods. MAb based immunodiagnostic kits such as EUSA (Enzyme Linked 
Immunosrbant Assay) and Immunodot can be simplified to the field level for use by 
farmers. Monoclonal antibodies to several viral and bacterial pathogens of fish and 
shellfish have been developed. It has been possible to develop rapid, simple, cheap, 
specific and sensitive MAb based immunodiagnostic kits for several microbial pathogens. 
In India, College of Fisheries, Mangalore has developed MAbs to Aeromonas hydrophila, 
EUS fungus Aphanomyces invadens and white spot virus of shrimp. 
Furthermore, detection of minute serological difference among bacterial and viral 
variants of fish and shellfish is possible by MAb based epitope analysis. This has helped 
immensely in serological and epidemiological studies. Monoclonal antibodies have also 
been used in detection of epitopes involved in pathogenesis for development of subunit 
vaccines. 
A serious bottleneck in developing standardized diagnostic assays for most 
important fish diseases is the lack of antifish immunoglobulin reagents. Hence there is also 
immense scope for developing Anti-fish immunoglobulin monoclonals using hybridoma 
technology. 
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